News

Dana-Farber/Boston Children’s researcher is part of a new Stand Up To Cancer campaign with Marvel Studios’ Avengers and American Airlines

Today, Stand Up To Cancer (SU2C), American Airlines and Marvel Studios’ Avengers: Infinity War announced a powerful collaboration as they team up in the fight against cancer.

Zeroing in on the fetal-to-adult hemoglobin switch and a new way to combat sickle cell disease

In this Vector report, researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center reveal how the protein, BCL11A, controls the switch in the body’s production of fetal hemoglobin to adult hemoglobin.

A breakthrough in our understanding of how red blood cells develop

In this Vector report, scientists make a new discovery about what drives the development of mature red blood cells after taking a deep dive into the molecular underpinnings of Diamond-Blackfan anemia.

Bursting with gene therapies and other innovative treatments, the overall survival rate for our blood and marrow transplant patients is exceeding expectations

Dana-Farber/Boston Children's is the only pediatric stem cell transplant center in the U.S. to exceed expected outcomes for allogeneic transplant patients in 2017.

Cancer researchers hit a bullseye with a new drug target for Ewing sarcoma

As reported in Vector, researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center have found that CDK12 inhibitors pack a particularly lethal punch to Ewing sarcoma, a rare cancer typically affecting children and young adults.

Dulling cancer therapy’s double-edged sword: A new way to block tumor recurrence

As reported in Vector, researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.

A new gene therapy transplantation technique could improve treatment of neurodegenerative disease

Alessandra Biffi, MD, led a study that shows the efficacy of a new gene therapy transplantation technique that could have future applications for treating neurodegenerative diseases.

New gene therapy clinical trial offers hope for sickle cell disease

David Williams, MD, discusses Dana-Farber/Boston Children's new gene therapy clinical trial for sickle cell disease in a live webchat.

MATCHing precision medicine to all kids with cancer

Sponsored by the National Institute of Cancer (NCI) and the Children’s Oncology Group (COG), the NCI-COG Pediatric MATCH trial will screen patients’ tumors for more than 160 gene mutations related to cancer.

Two Dana-Farber/Boston Children's faculty members elected to National Academy of Medicine

Two Dana-Farber/Boston Children's Cancer and Blood Disorders Center faculty members, Scott Allen Armstrong, MD, PhD, and Scott Pomeroy, MD, PhD, have been elected to the National Academy of Medicine (NAM).